Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn


Apply here

RCSI cancer research focuses on the molecular mechanisms of carcinogenesis, the identification of biomarkers, and the development of new anti-cancer agents for a variety of different cancer types, including breast carcinoma, colorectal cancer and neuroblastoma.

RCSI research in cancer plays a leading role in a number of large collaborative research networks/programmes, involving partners from industry, academia and clinical organisations, including Breast Predict, APO-Decide, Angiopredict, Mel-Plex, Molecular Therapeutic for Cancer Ireland, and Centre for Systems Medicine, which are described below:

Senior Academics/Researchers and Research Centres and Programmes in this area are listed below: 

Annette Byrne Physiology & Medical Physics View Annette Byrne's profile
Bryan Hennessy Medicine View Bryan Hennessy's profile
Ann Hopkins Surgery View Ann Hopkins' profile
Celine Marmion Pharmaceutical & Medicinal Chemistry View Celine Marmion's profile
Maria Morgan  Molecular & Cellular Therapeutics View Maria Morgan's profile 
Jochen Prehn Physiology & Medical Physics View Jochen Prehn's profile
Markus Rehm Physiology & Medical Physics View Markus Rehm's profile
Raymond Stallings Cancer Genetics, Office of Research & Innovation View Raymond's Stallings profile
Leonie Young Surgery View Leonie Young's Profile
Donal O'Shea Medicinal chemistry View Donal O'Shea's profile

Research Centres & Programmes in this Area


BREAST-PREDICT is the first, Irish Cancer Society-funded Collaborative Cancer Research Centre in Breast Cancer, and brings together researchers UCD, TCD, RCSI, DCU, NUIG and UCC, and the clinical trials group, ICORG. Its mission is to improve the understanding of how breast cancer spreads and becomes resistant to treatment, and develop better therapies.


FP7 funded collaborative project using systems medicine to deliver personalised medicine for colorectal cancer.


FP7 funded collaborative research project working towards personalised medicine for patients with metastatic colorectal cancer.


CSM Centre for Systems Medicine

The mission of the CSM is to undertake translational, multidisciplinary research that identifies proteins and genes implicated in human disease and utilizes systems biology and mathematical approaches in order to develop new prognostic tools for the treatment of cancer, neurological disorders and diabetes, and to develop more targeted therapies for patients.


Funded by the European Commission's Horizon 2020 Marie S. Curie Actions Programme to coordinate a research and training network, MEL-PLEX addresses current needs in academia and the private sector for researchers that have been interdisciplinarily trained, that can navigate confidently between academic, clinical and private sector research environments, and that have developed an innovative and creative mindset to progress research findings towards applications. In collaboration with Technical University Dresden, University of Luxembourg, University of Berne, University of Leuven, University of Heidelberg, University College Dublin, the Danish Cancer Research Center,Oncomark Ltd, Optimata Ltd, ProtATonce Ltd, Merrimack Pharmaceutical Ltd, Apogenix Ltd, Novartis Ltd., Massachusetts General Hospital, Galderma Pharma Ltd, and the Haadssah Hebrew University Medical Center, the scientific objective of MEL-PLEX is to employ molecular, mechanistic and mathematical systems-level disease understanding in order to improve the prognosis and treatment of primary and metastatic melanoma.

MCTI - Molecular Therapeutic for Cancer Ireland 

The MTCI is a Science Foundation Ireland (SFI)-funded Strategic Research Cluster which aims to discover and develop new anti-cancer drugs. Partners include DCU, UCD, TCD, and ICORG, funded by SFI under the Strategic Research Cluster Scheme.